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Abstract
Background: Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant and age-
dependent vascular disorder characterised mainly by mutations in the Endoglin (ENG) or activin
receptor-like kinase-1 (ALK1, ACVRL1) genes.
Methods: Here, we have identified 22 ALK1 mutations and 15 ENG mutations, many of which had
not previously been reported, in independent Spanish families afflicted with HHT.
Results: We identified mutations in thirty-seven unrelated families. A detailed analysis of clinical
symptoms was recorded for each patient analyzed, with a higher significant presence of pulmonary
arteriovenous malformations (PAVM) in HHT1 patients over HHT2. Twenty-two mutations in
ALK1 and fifteen in ENG genes were identified. Many of them, almost half, represented new
mutations in ALK1 and in ENG. Missense mutations in ENG and ALK1 were localized in a
tridimensional protein structure model.
Conclusion: Overall, ALK1 mutations (HHT2) were predominant over ENG mutations (HHT1)
in our Spanish population, in agreement with previous data from our country and other
Mediterranean countries (France, Italy), but different to Northern Europe or North America.
There was a significant increase of PAVM associated with HHT1 over HHT2 in these families.
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Hereditary Hemorrhagic Telangiectasia (HHT) (or Osler-
Weber-Rendu syndrome is an autosomal and age-depend-
ent vascular disorder (MIM #187300) [1,2] diagnosed
according to clinical criteria [3]: epistaxis, telangiectases
located in specific sites on the skin, and visceral involve-
ment, including arteriovenous malformations (AVMs) in
lung, brain and liver or telangiectases in the gastrointesti-
nal tract. These features, together with the dominant
inheritance, constitute the Curaçao criteria for the diagno-
sis of the disease, being positive if 3 out of the 4 criteria
are present in a patient.
Two main loci have been identified as the genes responsi-
ble for about 85% of the cases in the HHT disease: endo-
glin (ENG; 9q34) [4] mutated in HHT type 1 (MIM
#131195) and the activin receptor-like kinase-1 (ALK1 or
ACVRL1; 12q13) [5] affected in HHT type 2 (MIM
#601284). Recently, a third and a fourth loci for HHT
have been mapped to chromosomes 5 and 7 respectively,
but the specific genes have not yet been identified [6,7]. In
addition, the juvenile polyposis and hereditary haemor-
rhagic telangiectasia (JPHT), caused by MADH4 muta-
tions [8] and the primary pulmonary hypertension [9]
caused by BMPRII or ALK1 mutations are related diseases
showing clinical symptoms of HHT. Noteworthy in all
cases, members of the TGF-β system are involved, includ-
ing signalling receptors (ALK1, BMPRII), auxiliary recep-
tors (ENG) and transcriptional co-activators (Smad4).
TGF-β signals upon binding to type II receptor on the sur-
face of the cell. Once bound by TGF-β, type II receptor
recruits and phosphorylates type I receptor. Both TGF-β
receptors type I and II are serine/threonine kinases, and
the activated type I receptor phosphorylates the Smad
family of coactivators [10]. Endoglin interacts and coop-
erates with ALK1 in the TGF-β signalling pathway of
endothelial cells [11,12]. Recently it has been reported
that BMP9 and BMP10 are functional activators of ALK1
[13].
Protein expression studies in human umbilical vein
endothelial cells and peripheral blood activated mono-
cytes have proposed haploinsufficiency as the most likely
model explaining HHT1, since most mutated endoglin
alleles are not expressed on the cell surface [14-16]. Simi-
larly, haploinsufficiency may account for HHT2, although
the abundance of missense mutations affecting exons 7
and 8 suggests a misfunctioning of certain mutated ALK1
proteins [17].
To date, more than 500 mutants have been reported in
HHT Mutation database, in both ALK1 and ENG genes
[18]. Mutations in ALK1 are spread all over the 9 trans-
lated exons (from 2 to 10), whereas ENG mutations are
found in the 12 exons coding for the extracellular domain
and no mutant has ever been found in either transmem-
brane or cytoplasmic endoglin coding exons. Here, we
have identified 22 ALK1 mutations and 15 ENG muta-
tions, many of which had not previously been reported, as
origins of the HHT disease in independent Spanish fami-
lies.
Methods
Patient Samples, DNA Sequencing
Experimental research reported in this manuscript was
performed with the approval of the appropriate ethics
committee. Research was in compliance with the Helsinki
Declaration. Informed consent was obtained from all the
individuals participating in the study. They were sent to
the unit for screening purposes and most of them without
symptoms apart from epistaxis and the presence of muco-
cutaneous telangiectasias. Positive diagnoses of HHT were
based on Curaçao established criteria. A code was estab-
lished for each patient consisting in: family number,
number of member within the family, and the year of
sample reception. Genomic DNA was isolated from
peripheral blood using the Qia-amp Mini kit (Qiagen,
Germany). Mutations were analyzed by direct sequencing
of amplified exons for ALK1 and ENG. The fifteen ENG
exons and the nine ALK1 exons were amplified by PCR
using the HotMaster Polymerase (Eppendorf, Germany)
and sequenced using a cycle sequencing protocol
(Applied Biosystems, USA) with previously reported
primers [13,18,19]. ALK1 cDNA sequence derives from
the GenBank reference sequence: 4557242
(NM_000020.1). ENG cDNA sequence derives from the
GenBank reference sequence: 33871100 (BC014271.2).
All the new variants described in the present paper are
deposited at the Public HHT Mutation Database
(HHt.org). Nucleotides are numbered with c.1 corre-
sponding to the A of the ATG translation initiation codon
in the reference sequence.
Clinical screening was performed for all the patients in the
same way concerning lung (Contrast echocardiography
and thorax angio CT), liver (abdominal ultrasound and
angio CT) and brain (angio-MRI), regardless of their clin-
ical status. Thus in Tables 1 and 2 the clinical findings are
shown together with mutations.
Results
Clinical and molecular data of HHT1 and HHT2 Spanish 
families
Tables 1 and 2 summarise the HHT families studied with
their clinical features and identified mutations. In tables,
in clinical findings, E states for epistaxis, T for cutaneous
telangiectasia and, PAVM, HAVM and CAVM for pulmo-
nary, hepatic and cerebral arterio-venous malformations,
respectively. GB is gastrointestinal bleeding.Page 2 of 8
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each family was screened for mutations in ENG or ALK1
genes without previous linkage analysis. When new mis-
sense variants were found in one single affected member,
we made sure that the mutation was not a polymorphism
by sequencing 100 healthy individuals, including relatives
of the patient.
Endoglin mutations
Fifteen unrelated families had 13 different mutations con-
sisting in nonsense, missense, short deletion/insertion or
intronic mutations in ENG as shown in Additional file 1.
Exon 1
Family 80, with one affected member showed the mis-
sense change, c.14C>T; p.T5M, considered as a variant
[19]. Up to the present moment, we have not found any
other mutation responsible for the phenotype in this
patient. We are trying to get consent for more affected rel-
atives to establish the correlation "variant"/phenotype,
and we are re-screening the DNA for the presence of new
mutations.
Exon 2
Family 54 with one patient showing HAVM and PAVM
and a non-described deletion in exon 2, spanning 14 bp
across the exon 2-intron 2 boundary (c.212_219+6 del
14) according to HUGO (Hierarchical Union of Genes
from Operons) recommendations. The latter corresponds
to the six first nucleotides after exon 2. The deletion in
exon 2 is leading to a frameshift from aminoacid 71.
Exon 4
Family 51 was screened in one affected member showing
the missense mutation, c.392C>T; P131L [20]. This
patient showed PAVM and HAVM in addition to gastric
bleeding. Although some studies in literature consider it a
polymorphism and has been found as homozygous vari-
ant in unaffected subjects, we have found this mutation in
two different families, one previously reported by us with
3 affected members and an exact correlation genotype/
phenotype. In this particular family 51, other members
without symptoms did not present the mutation.
Exon 5
Family 30 with three patients showing the new missense
mutation, c.646A>G; p.K216Q, One of the three affected
members had a PAVM and HAVMs, and had suffered from
a brain abscess. Another patient had PAVMs.
Exon 6
Family 49 had a clinically diagnosed patient showing a
duplication c.771dupC [20] leading to a frameshift from
the 258 amino acid. The affected member showed PAVM
and CAVM. Family 42 represented by one affected mem-
ber showing the novel missense mutation c.812T>A;
p.I271N.
Exon 9a
Family 61 with one affected member showed the muta-
tion, c.1169G>A leading to a nonsense change, p.W390X,
not described so far.
Exon 9b
Family 67 with one affected member, showing the mis-
sense mutation c.1274C>G leading to the change
p.A425G. This patient had a PAVM.
Exon 10
Family 45 with three affected relatives, showing the non-
sense mutation c.1365C>T; p.Y455X. One of the affected
members had gastric bleeding and another a PAVM. This
mutation had previously been found by Westwoood and
Warner (2007; HHT Foundation database).
Family 73 with relatives in Portugal and Spain, harbored
the nonsense mutation (c.1414C>T) leading to p.Q472X
[21]. Two patients had GB and another PAVM.
Intron 11
A total of 5 different families showed mutations in this
intron, 3 of them having the same type of variant,
c.1686+5G>C, in spite of being independent families.
This mutation was present in affected members of families
number 3, 31 and 33.
In Family 3, four members were screened. Two patients
were affected of PAVMs: one of them suffered from a brain
abscess in addition of PAVM, a third member had CAVMs,
and the fourth showed CAVMs and HAVMs.
A third unrelated family, Family 31, had the same change
with a member suffering from PAVMs.
Family 33 with 2 affected members; one of the patients
showed PAVM and HAVM, and the other HAVM.
In Family 39 the mutation c.1686+1delG, was present in
one affected member. This member had gastric bleeding
and a PAVM. None of the three intron 11 mutations had
been previously published.
In Family 65 three affected members had the change,
c.1689+3A>G, two of them with PAVMs.
ALK1 mutations
A total of 22 independent families were found as carriers
of ALK1 mutations. These mutations were distributed
over 8 ALK1 coding exons, from 3 to 10. In addition,Page 3 of 8
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found Additional file 2
Exon 3
Family 34 showed a missense mutation, c.107G>A,
p.C36Y [22].
Family 74 represented by one patient had a deletion in
exon 3, c.144-145insG, mutation previously described
[23] leading to the frameshift, nonsense p.A49fs. The
patient had HAVM.
Exon 4
Family 53 presented a duplication
c.353_360dupAGCTGGCC leading to a frameshift muta-
tion, p.L121fs not previously described, in two affected
members, one of them with PAVM.
Intron 4
Family 35 had the change c.525+1G>A in intron 4,
detected in two members, both had PAVMs and one of
them in addition showed HAVM [27].
Exon 5
Family 41 showed a c.567delG deletion in one patient
leading to a p.G189fs new frameshift mutation.
Exon 6
Family 52 showed a nonsense new mutation, c.663G>A,
p.W221X, in two affected members with HAVMs.
Family 59 showed the mutation c.673_674delAG dele-
tion leading to a frameshift change p.S225fs, not previ-
ously described. The patient showed HAVMs.
Family 69 showed the same mutation of family 59,
c.673_674delAG leading to a frameshift p.S225fs. The
patient showed HAVMs.
Intron 6
Family 29 had in -2 position of intron 6 the mutation
c.773-2A>G [28].
Exon 7
Family 56 had two affected members with an ATGCGGC
duplication in exon 7 leading to a new p.L310 frameshift.
One member had HAVMs, while the other, 12 years old,
had no obvious symptoms.
Family 103 had an affected member with the mutation,
c.988G>T, a missense change p.D330Y [23].
Family 97 had a patient with the missense mutation,
c.1030T>C, resulting in a change Intron 7
Family 50 had the change c.1048+5G>T in intron 7
detected in 3 members, one affected of PAVMs and the
others (under 219 without clinical manifestations.
Exon 8
Family 57 had an affected member with the missense
mutation, c.1135G>A leading to p.E379K [20] and
HAVMs.
Family 44 with four patients showing the mutation,
c.1205G>A, leading to the missense change p.G402D not
reported before. Three of these patients had also PAVMs.
Family 46 had 3 affected relatives with the missense
mutation, c.1232G>A leading to p.R411Q [24], two of
them had PAVMs and one in addition HAVMs.
Family 60 had the missense mutation, c.1121G>A;
p.R374Q [17] and the affected member had PAVMs and
HAVMs, as well as gastric bleeding.
Exon 9
Family 38 had three members with a new missense muta-
tion, c.1261T>G; p.Y421D. One of them had PAVM.
Family 55 has a missense change, c.1345C>A; p. P449T
previously described [25]. The patient had PAVM, HAVM
and GB.
Intron 9
Family 62 had the new mutation c.1378-1G>T, involving
intron 9. The mutation was found in two affected mem-
bers.
Exon 10
Family 77 harbored the nonsense change c. 1435C>T;
p.R479EX [7] in two patients.
Family 36 had 2 members with the missense change
c.1405C>T; p.R484W, [26] one of them had an aortic fis-
tula at birth.
Among all the ENG and ALK1 mutations, missense muta-
tions are predicted to have an important impact on pro-
tein structure. Figure 1 shows the distribution in
theoretical 3D models of all the missense mutations
including the newly described in this work, for both,
endoglin and ALK1 proteins. Endoglin structure was
obtained according to [29] and is a theoretical ab initio
model. The theoretical ALK1 structure was obtained by
homology according to the procedure described [17].
Endoglin model is made for the extracellular domain,
while ALK1 model represents the cytoplasmic domain.
Overall, there is a predominant allocation of missense
mutations in the orphan domain (OD) of Endoglin. TwoPage 4 of 8
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lin in this paper fall in the OD, while the third one is
located in the Zona Pellucida Domain (ZPD), according
to the prediction [29].
In ALK1, most of the missense mutations, including the
newly described ones here, are clustered around the pock-
ets of the kinase domain as described [17].
Discussion
The first paper on mutation analysis in Spanish HHT
patients reported results on 17 families and now on 37
different families. All patients are familiar cases with no
sporadic case found in such cohort. We are presenting the
results obtained in a total of 74 clinically diagnosed
patients distributed among 37 independent families with
identified mutation. In addition, 15 more patients
The missense mutations previously described for the extracellular part of endoglin and the intracellular part of ALK1 are shown a  blue spheresFigure 1
The missense mutations previously described for the extracellular part of endoglin and the intracellular part of ALK1 are 
shown as blue spheres. The new mutations described in this report for both proteins appear as green spheres. The volume of 
the spheres is exclusively related to the size of the mutated residue side chain.
Plasma Membrane
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Newly described
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data are not presented in this study, since the correspond-
ing mutation analysis is not yet finished.
The actual rate of success in molecular diagnosis is around
75% (37 out of 49). In order to increase this rate, we are
currently using additional approaches like sequencing
SMAD 4 locus and MLPA (analysis of whole exonic dele-
tion or duplication mediated by ligation).
Out of the mutations, 15 were in ENG and 22 in ALK1.
Thus, in Spain, HHT due to the fact that mutation in ALK1
is higher than in ENG, following a similar trend (6 vs 11)
as in our previous studies [22]. This is in agreement with
the data from other mediterranean populations like
France [30] and Italy [31] but different from Canada, USA
[18,24] and Northern Europe populations [32] where
pathogenetic mutations in ENG are more frequent than in
ALK1.
Although the number of patients included in this study is
a bit too small, still we have taken advantage of drawing
some phenotype/genotype correlation features. Concern-
ing the clinical symptoms, when comparing Tables 1 and
2, the number of PAVMs was more frequent (55.1%) in
HHT1 than in HHT2 (33.3%). The slightly higher percent-
age of PAVMs found among the HHT2 patients versus pre-
vious reports may be explained by the highly sensitive
screening method used, contrast echocardiography with
injected bubbles, which can detect even small PAVMs.
Gastrointestinal bleeding (GB) and CAVMs were also
more frequent in HHT1 (13.8% and 10%, respectively)
than in HHT2 (5.5% and none, respectively). Finally,
HAVMs were slightly more frequent in HHT2 (36.1%)
than in HHT1 (34.4%). The same protocol of screening
(for lung, liver, brain) was applied for all patients regard-
less of the clinical status. These data are compatible with
previous reports on genotype phenotype correlations [33-
35], especially with the last which contains a large list of
patients from the French-North Italian network [34]. It is
also important to stress the fact that the severity of symp-
toms, especially the amount of epistaxis and frequency
increased tremendously in age, as HHT signs are age-
dependent. It is interesting at this point to consider
intronic mutations, and the age-dependence for the geno-
type/phenotype correlation, the latter will depend on the
rate of correct splicing from the wild type allele, versus the
aberrant one due to mutation. The splicing machinery
action maybe age-dependent, as seen in family 50, where
the father had symptoms while his two sons remained still
without clinical criteria.
Many of the mutations found are new; 8 in ALK1 and 8 in
ENG. It is also noteworthy the finding of 3 independent
families harboring the same mutation in intron 11 of
endoglin, a newly described mutation (c.1686+5G>C).
This may represent a hot spot mutation according to our
series data in Spanish population. Alternatively a single
mutational event could take place in a common ancestor
of the three families which are now apparently unrelated,
then representing a founder effect in the Spanish popula-
tion.
The mutations found in ENG and ALK1 are spread all over
the different exons and some of them were intronic. In
ENG, along exons 1(1), 2(1), 4 (2), 5(1), 6 (2), 9a (1), 9b
(1) and 11(1), as well as intron 11(3). In ALK1, along
exons 3 (2), 4 (1), 5 (1), 6 (2), 7 (3), 8 (4), 9 (2) and 10
(2), as well as introns 2 (1), 4 (1), 6 (1), 7(1) and 9 (1).
Haploinsufficiency is the commonly accepted pathogenic
model especially for HHT1 (17). It has been shown that
missense endoglin mutants are not found expressed on
the cell surface [14,16,22] suggesting that these missense
mutations have an impact on the protein structure. Inter-
estingly, there is a slightly predominant allocation of mis-
sense pathogenic mutations in the OD of endoglin
(Figure 1, top), although other mutations are also present
in the ZPD. This argues in favour of an important role of
OD and ZPD in the endoglin post-translational modifica-
tions, folding and export to the outside of the membrane.
In the case of ALK1, most missense mutations involve the
kinase domains. In the latter case, a less active kinase may
be the origin of the disease, rather than a complete loss of
half of the protein (haploinsufficiency). In fact, in [22] we
have shown that some ALK1 missense mutants are
expressed on the cell surface. When comparing the ALK1
missense versus nonsense or frameshift mutations (null
alleles), we have not found correlations in terms of pre-
dominant clinical symptoms in one of the classes. Out of
22 ALK1 families, 11 had missense and 11 had nonsense
mutations, the frequency of internal arteriovenous mal-
formations was exactly the same, 8/11 in both classes, sug-
gesting that sometimes missense alleles may not be
functional, or even deleterious.
Conclusion
- A series of 37 mutations have been found as origins of
HHT, both type 1 and 2 in Spanish families
- Out of 37, almost half of them were newly described
mutations.
- There is a predominance of mutations in ALK1 (22) ver-
sus 15 in Endoglin as it is current for other mediterranean
countries
- We see a predominance of pulmonary arteriovenous
malformations in HHT1 (52% of the screened patients)Page 6 of 8
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venous malformations is slighty more prevalent.
- Missense mutations in ALK1 cluster predominantly in
kinase domains of exons 7 and 8, whereas the less abun-
dant missense mutations found in Endoglin are scattered
in the extracellular domain of the protein.
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